Potential conflict of interest: S.M., C.T.S., and M.R.S. engage in promotional speaking for UCB Pharma or Glaxo SmithKline, the manufacturers of levetiracetam and lamotrigine, respectively. The total amounts for each person are under $10,000 per year. These same physicians also participate in clinical trials for UCB Pharma through Thomas Jefferson University.
Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein†
Article first published online: 18 MAR 2009
Copyright © 2009 American Neurological Association
Annals of Neurology
Volume 65, Issue 4, pages 448–456, April 2009
How to Cite
Mintzer, S., Skidmore, C. T., Abidin, C. J., Morales, M. C., Chervoneva, I., Capuzzi, D. M. and Sperling, M. R. (2009), Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol., 65: 448–456. doi: 10.1002/ana.21615
- Issue published online: 27 APR 2009
- Article first published online: 18 MAR 2009
- Manuscript Accepted: 10 NOV 2008
- Manuscript Revised: 8 NOV 2008
- Manuscript Received: 15 AUG 2008
- Epilepsy Foundation through the Edna Flaig Evans Trust
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.